BET-independent MLV-based vectors target away from promoters and regulatory elements

Molecular Therapy Nucleic Acids

Volumn 3, Issue , 2014, Pages e179-11

  El Ashkar, Sara ^a   De Rijck, Jan ^a   Demeulemeester, Jonas ^a   Vets, Sofie ^a   Madlala, Paradise ^a,b   Cermakova, Katerina ^a   Debyser, Zeger ^a   Gijsbers, Rik ^a,c  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c KU LEUVEN   (Belgium)

Author keywords

deletion and modification Gene vectors; Gene insertion

Indexed keywords

ALANINE; BET PROTEIN; BINDING PROTEIN; INTEGRASE; TRYPTOPHAN; UNCLASSIFIED DRUG; VIRUS VECTOR; BROMODOMAIN AND EXTRA TERMINAL FAMILY PROTEIN; PEPTIDES AND PROTEINS;

AMINO ACID SUBSTITUTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE TARGETING; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IN VITRO STUDY; MURINE LEUKEMIA VIRUS; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN LOCALIZATION; PROTEIN MOTIF; RETROVIRUS; TRANSCRIPTION INITIATION SITE; VIRAL GENE DELIVERY SYSTEM; VIRUS DNA CELL DNA INTERACTION; WILD TYPE; MUTAGENESIS; NONHUMAN; PROTEIN INTERACTION; VIRAL GENE THERAPY;

EID: 84905219960     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2014.33     Document Type: Article

References (49)

1. Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
2. Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
3. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
4. Avedillo Díez, I, Zychlinski, D, Coci, EG, Galla, M, Modlich, U, Dewey, RA et al. (2011). Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy. Mol Pharm 8: 1525-1537.
5. Cavazzana-Calvo, M, Hacein-Bey, S, de Saint Basile, G, Gross, F, Yvon, E, Nusbaum, P et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672. (Pubitemid 30241569)
6. Mukherjee, S and Thrasher, AJ (2013). Gene therapy for PIDs: progress, pitfalls and prospects. Gene 525: 174-181.
7. Schröder, AR, Shinn, P, Chen, H, Berry, C, Ecker, JR and Bushman, F (2002). HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110: 521-529. (Pubitemid 35232295)
8. Wu, X, Li, Y, Crise, B and Burgess, SM (2003). Transcription start regions in the human genome are favored targets for MLV integration. Science 300: 1749-1751. (Pubitemid 36712571)
9. Mitchell, RS, Beitzel, BF, Schroder, AR, Shinn, P, Chen, H, Berry, CC et al. (2004). Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2: E234.
10. De Ravin, SS, Su, L, Theobald, N, Choi, U, Macpherson, JL, Poidinger, M et al. (2014). Enhancers are major targets for murine leukemia virus vector integration. J Virol 88: 4504-4513.
11. LaFave, MC, Varshney, GK, Gildea, DE, Wolfsberg, TG, Baxevanis, AD and Burgess, SM (2014). MLV integration site selection is driven by strong enhancers and active promoters. Nucleic Acids Res 42: 4257-4269.
12. Cherepanov, P, Maertens, G, Proost, P, Devreese, B, Van Beeumen, J, Engelborghs, Y et al. (2003). HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem 278: 372-381. (Pubitemid 36043586)
13. Llano, M, Saenz, DT, Meehan, A, Wongthida, P, Peretz, M, Walker, WH et al. (2006). An essential role for LEDGF/p75 in HIV integration. Science 314: 461-464. (Pubitemid 44628966)
14. Hombrouck, A, De Rijck, J, Hendrix, J, Vandekerckhove, L, Voet, A, De Maeyer, M et al. (2007). Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. PLoS Pathog 3: e47.
15. Shun, MC, Raghavendra, NK, Vandegraaff, N, Daigle, JE, Hughes, S, Kellam, P et al. (2007). LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev 21: 1767-1778. (Pubitemid 47076476)
16. De Rijck, J, Vandekerckhove, L, Gijsbers, R, Hombrouck, A, Hendrix, J, Vercammen, J et al. (2006). Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J Virol 80: 11498-11509. (Pubitemid 44788865)
17. Ciuffi, A, Ronen, K, Brady, T, Malani, N, Wang, G, Berry, CC et al. (2009). Methods for integration site distribution analyses in animal cell genomes. Methods 47: 261-268.
18. Marshall, HM, Ronen, K, Berry, C, Llano, M, Sutherland, H, Saenz, D et al. (2007). Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS One 2: e1340.
19. Gijsbers, R, Ronen, K, Vets, S, Malani, N, De Rijck, J, McNeely, M et al. (2010). LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol Ther 18: 552-560.
20. De Rijck, J, Bartholomeeusen, K, Ceulemans, H, Debyser, Z and Gijsbers, R (2010). High-resolution profiling of the LEDGF/p75 chromatin interaction in the ENCODE region. Nucleic Acids Res 38: 6135-6147.
21. Schrijvers, R, De Rijck, J, Demeulemeester, J, Adachi, N, Vets, S, Ronen, K et al. (2012). LEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs. PLoS Pathog 8: e1002558.
22. Sharma, A, Larue, RC, Plumb, MR, Malani, N, Male, F, Slaughter, A et al. (2013). BET proteins promote efficient murine leukemia virus integration at transcription start sites. Proc Natl Acad Sci USA 110: 12036-12041.
23. De Rijck, J, de Kogel, C, Demeulemeester, J, Vets, S, El Ashkar, S, Malani, N et al. (2013). The BET family of proteins targets moloney murine leukemia virus integration near transcription start sites. Cell Rep 5: 886-894.
24. Gupta, SS, Maetzig, T, Maertens, GN, Sharif, A, Rothe, M, Weidner-Glunde, M et al. (2013). Bromo-and extraterminal domain chromatin regulators serve as cofactors for murine leukemia virus integration. J Virol 87: 12721-12736.
25. Devaiah, BN and Singer, DS (2013). Two faces of brd4: mitotic bookmark and transcriptional lynchpin. Transcription 4: 13-17.
26. Roth, MJ (1991). Mutational analysis of the carboxyl terminus of the Moloney murine leukemia virus integration protein. J Virol 65: 2141-2145.
27. Jonsson, CB, Donzella, GA, Gaucan, E, Smith, CM and Roth, MJ (1996). Functional domains of Moloney murine leukemia virus integrase defined by mutation and complementation analysis. J Virol 70: 4585-4597.
28. Zhang, W, Prakash, C, Sum, C, Gong, Y, Li, Y, Kwok, JJ et al. (2012). Bromodomaincontaining protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem 287: 43137-43155.
29. Felice, B, Cattoglio, C, Cittaro, D, Testa, A, Miccio, A, Ferrari, G et al. (2009). Transcription factor binding sites are genetic determinants of retroviral integration in the human genome. PLoS One 4: e4571.
30. Trobridge, GD, Miller, DG, Jacobs, MA, Allen, JM, Kiem, HP, Kaul, R et al. (2006). Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci USA 103: 1498-1503. (Pubitemid 43191194)
31. Nowrouzi, A, Dittrich, M, Klanke, C, Heinkelein, M, Rammling, M, Dandekar, T et al. (2006). Genome-wide mapping of foamy virus vector integrations into a human cell line. J Gen Virol 87(Pt 5): 1339-1347.
32. Barski, A, Cuddapah, S, Cui, K, Roh, TY, Schones, DE, Wang, Z et al. (2007). Highresolution profiling of histone methylations in the human genome. Cell 129: 823-837. (Pubitemid 46802390)
33. Taverna, SD, Li, H, Ruthenburg, AJ, Allis, CD and Patel, DJ (2007). How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol 14: 1025-1040. (Pubitemid 350060344)
34. Zychlinski, D, Schambach, A, Modlich, U, Maetzig, T, Meyer, J, Grassman, E et al. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 16: 718-725. (Pubitemid 351426173)
35. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Bartholomae, CC, Ranzani, M et al. (2009). The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119: 964-975.
36. Modlich, U, Navarro, S, Zychlinski, D, Maetzig, T, Knoess, S, Brugman, MH et al. (2009). Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 17: 1919-1928.
37. Newrzela, S, Cornils, K, Li, Z, Baum, C, Brugman, MH, Hartmann, M et al. (2008). Resistance of mature T cells to oncogene transformation. Blood 112: 2278-2286.
38. Hargrove, PW, Kepes, S, Hanawa, H, Obenauer, JC, Pei, D, Cheng, C et al. (2008). Globin lentiviral vector insertions can perturb the expression of endogenous genes in betathalassemic hematopoietic cells. Mol Ther 16: 525-533. (Pubitemid 351314992)
39. Moiani, A, Miccio, A, Rizzi, E, Severgnini, M, Pellin, D, Suerth, JD et al. (2013). Deletion of the LTR enhancer/promoter has no impact on the integration profile of MLV vectors in human hematopoietic progenitors. PLoS One 8: e55721.
40. Modlich, U, Schambach, A, Brugman, MH, Wicke, DC, Knoess, S, Li, Z et al. (2008). Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia 22: 1519-1528.
41. Derse, D, Crise, B, Li, Y, Princler, G, Lum, N, Stewart, C et al. (2007). Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses. J Virol 81: 6731-6741. (Pubitemid 46878077)
42. Malik, HS, Burke, WD and Eickbush, TH (1999). The age and evolution of non-LTR retrotransposable elements. Mol Biol Evol 16: 793-805. (Pubitemid 29260833)
43. Zhu, Y, Zou, S, Wright, DA and Voytas, DF (1999). Tagging chromatin with retrotransposons: target specificity of the Saccharomyces Ty5 retrotransposon changes with the chromosomal localization of Sir3p and Sir4p. Genes Dev 13: 2738-2749. (Pubitemid 29508560)
44. Kirchner, J, Connolly, CM and Sandmeyer, SB (1995). Requirement of RNA polymerase III transcription factors for in vitro position-specific integration of a retroviruslike element. Science 267: 1488-1491.
45. Ciuffi, A, Llano, M, Poeschla, E, Hoffmann, C, Leipzig, J, Shinn, P et al. (2005). A role for LEDGF/p75 in targeting HIV DNA integration. Nat Med 11: 1287-1289. (Pubitemid 41752906)
46. Cherepanov, P, Ambrosio, AL, Rahman, S, Ellenberger, T and Engelman, A (2005). Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci USA 102: 17308-17313. (Pubitemid 41740862)
47. Vets, S, De Rijck, J, Brendel, C, Grez, M, Bushman, F, Debyser, Z et al. (2013). Transient Expression of an LEDGF/p75 Chimera Retargets Lentivector Integration and Functionally Rescues in a Model for X-CGD. Mol Ther Nucleic Acids 2: e77.
48. Brady, T, Lee, YN, Ronen, K, Malani, N, Berry, CC, Bieniasz, PD et al. (2009). Integration target site selection by a resurrected human endogenous retrovirus. Genes Dev 23: 633-642.
49. Leroy, G, Chepelev, I, Dimaggio, PA, Blanco, MA, Zee, BM, Zhao, K, et al. (2012). Proteogenomic characterization and mapping of nucleosomes decoded by Brd and HP1 proteins. Genome Biol 13: R68.